BCIQ Profiles

Company Profile Report

Aug. 22 Company Quick Takes: Innovent, Lilly in biologics deal; plus Sobi, Gilead, Themis-Merck, Iconic-Novartis, GW, BeiGene, Clearside, Inex Innovations

Innovent, Lilly in third biologics deal
Innovent Biologics Inc. (HKEX:1801) in-licensed Chinese rights to OXM3 from Eli Lilly and Co. (NYSE:LLY) to treat diabetes. The oxyntomodulin analog -- a dual agonist of GLP-1R and GCGR -- also has the potential to be developed for obesity and non-alcoholic steatohepatitis (NASH). Financial terms were undisclosed. This is Innovent's third collaboration with Lilly; the first two

Read the full 626 word article

How to gain access

Continue reading with a
two-week free trial.